Centessa Pharmaceuticals plc (NASDAQ:CNTA) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) have received a consensus rating of “Buy” from the seven brokerages that are presently covering the stock, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy recommendation. The average 12-month price target among brokers that have issued a report on the stock in the last year is $25.83.

Several equities analysts recently issued reports on CNTA shares. Guggenheim restated a “buy” rating on shares of Centessa Pharmaceuticals in a research note on Monday, February 10th. TD Cowen started coverage on Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They set a “buy” rating on the stock.

Centessa Pharmaceuticals Stock Performance

Shares of CNTA opened at $16.63 on Friday. The business’s fifty day moving average price is $16.71 and its 200 day moving average price is $15.87. Centessa Pharmaceuticals has a 12-month low of $7.75 and a 12-month high of $19.09. The stock has a market capitalization of $2.19 billion, a PE ratio of -10.87 and a beta of 1.53. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52.

Insiders Place Their Bets

In other news, CEO Saurabh Saha sold 87,496 shares of the firm’s stock in a transaction on Friday, December 6th. The stock was sold at an average price of $18.46, for a total transaction of $1,615,176.16. Following the transaction, the chief executive officer now directly owns 575,661 shares of the company’s stock, valued at approximately $10,626,702.06. This trade represents a 13.19 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Gregory M. Weinhoff sold 10,000 shares of the firm’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $17.66, for a total value of $176,600.00. Following the transaction, the insider now directly owns 183,266 shares in the company, valued at $3,236,477.56. This trade represents a 5.17 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 456,981 shares of company stock valued at $7,814,333 over the last three months. Company insiders own 11.59% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. GF Fund Management CO. LTD. acquired a new position in shares of Centessa Pharmaceuticals during the fourth quarter valued at $31,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Centessa Pharmaceuticals by 47.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock valued at $40,000 after purchasing an additional 826 shares during the period. GAMMA Investing LLC increased its holdings in shares of Centessa Pharmaceuticals by 29.1% during the fourth quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock valued at $64,000 after purchasing an additional 865 shares during the period. Barclays PLC increased its holdings in shares of Centessa Pharmaceuticals by 1,414.9% during the fourth quarter. Barclays PLC now owns 5,302 shares of the company’s stock valued at $89,000 after purchasing an additional 4,952 shares during the period. Finally, BNP Paribas Financial Markets acquired a new position in shares of Centessa Pharmaceuticals during the fourth quarter valued at $162,000. 82.01% of the stock is owned by institutional investors and hedge funds.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.